Novo Nordisk Gets European Regulator's Positive Opinion on Wegovy Label Update

MT Newswires Live07-26

Novo Nordisk (NVO) said Thursday the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on an update to Wegovy's label, reflecting risk reduction of major adverse cardiovascular events.

The update is based on trial data showing Wegovy significantly reduced the risk of major adverse cardiovascular events, such as cardiovascular death, nonfatal heart attack or nonfatal stroke, by 20% in adults with cardiovascular disease who are either overweight or obese and without diabetes, the company said.

The label update will also include reduced risk of heart failure composite endpoint, cardiovascular death or death from any cause, the company said.

Novo Nordisk expects the label update to be implemented in about a month.

The company's shares fell 1.4% in recent trading Thursday.

Price: 129.73, Change: -1.87, Percent Change: -1.42

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2454804677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-26 00:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2454804677","market":"sg","top_or_hot":-1,"title":"Novo Nordisk Gets European Regulator's Positive Opinion on Wegovy Label Update","media":"MT Newswires Live","content":"<html><body><p> Novo Nordisk (NVO) said Thursday the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on an update to Wegovy's label, reflecting risk reduction of major adverse cardiovascular events.</p><p>The update is based on trial data showing Wegovy significantly reduced the risk of major adverse cardiovascular events, such as cardiovascular death, nonfatal heart attack or nonfatal stroke, by 20% in adults with cardiovascular disease who are either overweight or obese and without diabetes, the company said.</p><p>The label update will also include reduced risk of heart failure composite endpoint, cardiovascular death or death from any cause, the company said.</p><p>Novo Nordisk expects the label update to be implemented in about a month.</p><p>The company's shares fell 1.4% in recent trading Thursday.</p><p>Price: 129.73, Change: -1.87, Percent Change: -1.42</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Gets European Regulator's Positive Opinion on Wegovy Label Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Gets European Regulator's Positive Opinion on Wegovy Label Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-26 00:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk (NVO) said Thursday the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on an update to Wegovy's label, reflecting risk reduction of ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2454804677","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454804677","pubTimestamp":1721924641,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  said Thursday the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on an update to Wegovy's label, reflecting risk reduction of major adverse cardiovascular events.The update is based on trial data showing Wegovy significantly reduced the risk of major adverse cardiovascular events, such as cardiovascular death, nonfatal heart attack or nonfatal stroke, by 20% in adults with cardiovascular disease who are either overweight or obese and without diabetes, the company said.The label update will also include reduced risk of heart failure composite endpoint, cardiovascular death or death from any cause, the company said.Novo Nordisk expects the label update to be implemented in about a month.The company's shares fell 1.4% in recent trading Thursday.Price: 129.73, Change: -1.87, Percent Change: -1.42","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4532":"文艺复兴科技持仓","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK7104":"黄金","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)"},"translate_title":"诺和诺德获得欧洲监管机构对Wegovy标签更新的积极意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk (NVO) said Thursday the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on an update to Wegovy's label, reflecting risk reduction of major adverse cardiovascular events.The update is based on trial data showing Wegovy significantly reduced the risk of major adverse cardiovascular events, such as cardiovascular death, nonfatal heart attack or nonfatal stroke, by 20% in adults with cardiovascular disease who are either overweight or obese and without diabetes, the company said.The label update will also include reduced risk of heart failure composite endpoint, cardiovascular death or death from any cause, the company said.Novo Nordisk expects the label update to be implemented in about a month.The company's shares fell 1.4% in recent trading Thursday.Price: 129.73, Change: -1.87, Percent Change: -1.42","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.3","shortVersion":"4.26.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454804677"}